|
|
|
|
Astex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference
Cambridge, England, 1st December, 2008 - Astex Therapeutics Limited, the leading fragment based drug discovery company, today announced that it is to present key findings on two of its clinical stage compounds, AT7519 and AT9283, at the 50th...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid...
|
|
|
Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of
SOUTH SAN FRANCISCO, Calif., Dec.1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related...
|
|
|
Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of
SOUTH SAN FRANCISCO, Calif., Dec.1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related...
|
|
|
Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of
(GlobeNewswire via COMTEX) -- HNAB | Quote | Chart | News | PowerRating -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related...
|
|
|
ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma
_ ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma.
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRwire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: - ), a biopharmaceutical company focused on the development and commercialization...
|
|
|
Lodge is place of comfort, support for cancer patients
When you have cancer, you want the absolute best care and treatment that is available -no matter how far you might travel to get it.For Poughkeepsie resident Philip Mestman, treating his prostate cancer six years ago meant trying a...
|
|
|
Proteolix to present phase II trial data of carfilzomib at 50th meeting of ASH
Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, would present the data from two ongoing phase II clinical trials of carfilzomib in...
|
|
|
The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of Phase 1B Study of
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in...
|
|
|
[Lymphoma and Myeloma] Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphom
From the Medizinische Klinik und Poliklinik II, Universittsklinikum Wrzburg; Pathologisches Institut, Universittsklinikum Wrzburg, Wrzburg; Krankenhaus Mnchen-Schwabing, 1.Medizinische Abteilung, Mnchen; Allgemeines Krankenhaus St.
|
|
|
GP who altered patient's records after death cleared of misconduct A YORKSHIRE doctor who failed to realise a
A General Medical Council Fitness to Practise panel found Dr Paul Pickering's fitness to practise was not impaired by his treatment of the 67-year-old man, known only as Patient A, in February 2006.It ruled Dr Pickering's 'normal high...
|
|
|
CombinatoRx Announces Availability of Abstracts on ASH Website
Oral Presentations: Poster Presentation: Abstracts 252, 847 and 2663 are collaborative efforts with Douglas W.McMillin, Constantine Mitsiades and Kenneth C. Anderson at the Jerome Lipper Multiple Myeloma Center, Dana-Farber...
|
|
|
Aggressive Cancer Treatment, Prevention Efforts Drop Cancer Rates
New cancer diagnosis rates decreased from 1999 to 2005 by 0.8% a year, according to a newly released report by the National Cancer Institute, the US Centers for Disease Control and the American Cancer Society.In addition, death rates from...
|
|
|
Protein arrests cervical cancer growth
A transforming growth factor involved in cell differentiation has been shown to arrest the growth of cervical cancer cells by inhibiting the activity of the enzyme telomerase in a mouse model, Monash University researchers report.Bone...
|
|
|
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hemat
Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., November 25, 2008 /PRNewswire/ -- Proteolix, Inc., a leader in the...
|
|
|
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hemat
Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., Nov.25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery...
|
|
|
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hemat
Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., Nov.25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery...
|
|
|
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hemat
Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., November 25, 2008 /PRNewswire/ -- Proteolix, Inc., a leader in the...
|
|
|
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hemat
SOUTH SAN FRANCISCO, Calif.Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York In addition to the oral...
|
|
|
CombinatoRx Announces Availability of Abstracts on ASH Website
- CombinatoRx, Incorporated (Nasdaq: CRXX) today announced the publication of accepted abstracts on the American Society of Hematology (ASH) website.This research will be presented at the 50th Annual Meeting of the American Society of...
|
